生长抑素治疗甲状腺相关性眼病的疗效分析

Treatment for thyriod associated ophthalmopathy with Octreotide

目的探讨生长抑素（奥曲肽）治疗甲状腺相关性眼病的疗效。方法将42例甲状腺相关性眼病（TAO）患者随机分为A、B二组，每组21例。A组眶内注射生长抑素（奥曲肽）100μg；B组眶内注射地塞米松5mg。各组均每2周注射1次，连续注射6次。结果（1）眼球突出度：A组治疗后3个月较治疗前明显减轻（P〈0．05）；B组治疗后3个月较治疗前无明显减轻（P〉0．05）；（2）眼球运动障碍及复视例数：A组治疗后（23．8％）比治疗前（57．1％）明显减少（P〈0．05）；B组治疗后（33．3％）比治疗前（52．4％）无明显减少（P〉0．05）。结论眶内注射生长抑素治疗甲状腺相关性眼病是有效和安全的。

Objective To appraise the effect of intraorbital injection of Octreotide in patients with thyroid associated ophthalmopathy （TAO）. Methods Forty-two cases of patients with TAO were randomly allocated into two groups： patients in group A was injected with 0.1mg of Octreotide; patients in group B was injected with 5mg dexamethasone. Each group received the injection once every two weeks for six times. Re- suits （ 1 ） The degree of exophthalmos in group A was significantly lower than that in group B at 3 months post-injection （P〈 0.05 ） ; （2） The case of eyeball motion hinder and diplopia in group A was significantly less than that in group B at 3 months post-injection （P〈0.05）. Conclusions Treatment for TAO with intraorbital injection of Octreotide is effective and safe.